These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Kimura H; Ito Y; Kawabe S; Gotoh K; Takahashi Y; Kojima S; Naoe T; Esaki S; Kikuta A; Sawada A; Kawa K; Ohshima K; Nakamura S Blood; 2012 Jan; 119(3):673-86. PubMed ID: 22096243 [TBL] [Abstract][Full Text] [Related]
25. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders. Onishi Y; Onodera K; Fukuhara N; Kato H; Ichikawa S; Fujiwara T; Yokoyama H; Yamada-Fujiwara M; Harigae H Int J Hematol; 2022 Jun; 115(6):873-881. PubMed ID: 35274195 [TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin. Goodlad JR Surg Pathol Clin; 2017 Jun; 10(2):429-453. PubMed ID: 28477890 [TBL] [Abstract][Full Text] [Related]
27. NK-cell repertoire is feasible for diagnosing Epstein-Barr virus-infected NK-cell lymphoproliferative disease and evaluating the treatment effect. Sawada A; Sato E; Koyama M; Higuchi B; Kusuki S; Kim JY; Takeshita Y; Sakata A; Sakata N; Okamura T; Yasui M; Inoue M; Kawa K Am J Hematol; 2006 Aug; 81(8):576-81. PubMed ID: 16823820 [TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases. Kim WY; Montes-Mojarro IA; Fend F; Quintanilla-Martinez L Front Pediatr; 2019; 7():71. PubMed ID: 30931288 [TBL] [Abstract][Full Text] [Related]
29. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK; Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913 [TBL] [Abstract][Full Text] [Related]
30. [Delayed diagnosis of hydroa vacciniforme-like lymphoproliferative disorder in a patient with skin rashes]. Umeki Y; Ikeda M; Nakahara W; Asako M; Matsuoka Y; Terakawa T; Matsunaga H; Tadokoro R; Sekiguchi M; Matsui T; Oka K; Higuchi K; Sawada A; Inoue M; Ueda S Rinsho Ketsueki; 2023; 64(3):209-213. PubMed ID: 37019675 [TBL] [Abstract][Full Text] [Related]
31. Characterization of T-/natural killer cell lymphoproliferative neoplasms associated with systemic, chronic, active Epstein-Barr virus in adults: A report of 5 cases in a Western population. Murga-Zamalloa C; Stone MB; Gutierrez MG; Hippalgaonkar NR; Tariq H; Sadeh M; Mehta A; Khan I; Alkan S; Inamdar KV; Wilcox R; Behdad A Am J Clin Pathol; 2024 Jun; 161(6):586-597. PubMed ID: 38345307 [TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features. Syrykh C; Péricart S; Lamaison C; Escudié F; Brousset P; Laurent C Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282778 [TBL] [Abstract][Full Text] [Related]
33. Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases. Guo N; Chen Y; Wang Y; Huang Y; Feng Y; Li M; Rao H Diagn Pathol; 2019 Jul; 14(1):82. PubMed ID: 31315684 [TBL] [Abstract][Full Text] [Related]
34. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Kawabe S; Ito Y; Gotoh K; Kojima S; Matsumoto K; Kinoshita T; Iwata S; Nishiyama Y; Kimura H Cancer Sci; 2012 Aug; 103(8):1481-8. PubMed ID: 22497716 [TBL] [Abstract][Full Text] [Related]
35. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. Fournier B; Boutboul D; Bruneau J; Miot C; Boulanger C; Malphettes M; Pellier I; Dunogué B; Terrier B; Suarez F; Blanche S; Castelle M; Winter S; Delecluse HJ; Molina T; Picard C; Ehl S; Moshous D; Galicier L; Barlogis V; Fischer A; Neven B; Latour S J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32812031 [TBL] [Abstract][Full Text] [Related]
36. Hydroa vacciniforme lymphoproliferative disorder: a retrospective study of 42 paediatric cases. Zhang Y; Liu Y; Xu J; Liang Y; Xu Z Eur J Dermatol; 2024 Apr; 34(2):144-149. PubMed ID: 38907544 [TBL] [Abstract][Full Text] [Related]
37. [Diagnosis and management of EBV-positive lymphoproliferative disorders]. Arai A Rinsho Ketsueki; 2023; 64(8):764-771. PubMed ID: 37673629 [TBL] [Abstract][Full Text] [Related]
38. Hydroa vacciniforme: a distinctive form of Epstein-Barr virus-associated T-cell lymphoproliferative disorders. Iwatsuki K; Miyake T; Hirai Y; Yamamoto T Eur J Dermatol; 2019 Feb; 29(1):21-28. PubMed ID: 30998212 [TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions: A Case Report. Xiao HJ; Li J; Song HM; Li ZH; Dong M; Zhou XG Medicine (Baltimore); 2016 Feb; 95(5):e2676. PubMed ID: 26844502 [TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Cohen JI; Kimura H; Nakamura S; Ko YH; Jaffe ES Ann Oncol; 2009 Sep; 20(9):1472-1482. PubMed ID: 19515747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]